Here’s how analysts see CTI BioPharma Corp. (NASDAQ:CTIC) after this past week.

March 22, 2018 - By Vivian Currie

 Here's how analysts see CTI BioPharma Corp. (NASDAQ:CTIC) after this past week.

CTI BioPharma Corp. (NASDAQ:CTIC) Ratings Coverage

Among 4 analysts covering CTI BioPharma Corp (NASDAQ:CTIC), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. CTI BioPharma Corp had 5 analyst reports since August 15, 2015 according to SRatingsIntel. The stock has “Buy” rating by Roth Capital on Saturday, August 15. WallachBeth Capital downgraded the shares of CTIC in report on Monday, November 9 to “Hold” rating. Below is a list of CTI BioPharma Corp. (NASDAQ:CTIC) latest ratings and price target changes.

07/03/2018 Broker: JMP Securities Rating: Outperform New Target: $8 Initiates Coverage On
23/02/2018 Broker: Oppenheimer Rating: Outperform New Target: $5 Initiates Coverage On

The stock increased 0.76% or $0.03 during the last trading session, reaching $3.96. About 274,275 shares traded. CTI BioPharma Corp. (NASDAQ:CTIC) has declined 4.09% since March 22, 2017 and is downtrending. It has underperformed by 20.79% the S&P500.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. The company has market cap of $261.27 million. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. It currently has negative earnings. The firm is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.